Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie’s mission ...

Aquestive Therapeutics, Inc. (NASDAQ: AQST) ('Aquestive” or the 'Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...

Eli Lilly faces a pivotal moment as its stock experiences a slight pullback. Investors are eyeing its upcoming earnings ...

AstraZeneca on Monday announced plans to invest $50 billion in its US operations by 2030, a sweeping commitment that includes ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are ...

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will increase.

Monthly trends further highlighted volatility: FDI peaked in September and November 2024, followed by inconsistent flows for ...

-- For many of these favored stocks, the share prices are close to the consensus price targets, or even exceed them. Most analysts set 12-month price targets. So we made one more cut to 15 stocks for ...

Eli Lilly (LLY) ended the recent trading session at $762.18, demonstrating a -1.23% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14% ...